Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00915200 · ClinicalTrials.gov registry record · Phase 2
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT00915200 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 114 participants.
The verdict
NCT00915200, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
The study is designed to test if the combination of two potent antioxidant nutritional supplements, N-acetylcysteine and the milk thistle extract silibin, is capable of correcting the shedding of urine protein, the oxidative stress, and the inflammation in patients with type 2 diabetes mellitus and diabetic kidney disease.
Interventions
- DIETARY_SUPPLEMENT N-acetylcysteine
- DIETARY_SUPPLEMENT silibin
- DIETARY_SUPPLEMENT high-dose silibin
- DIETARY_SUPPLEMENT N-acetylcysteine placebo
- DIETARY_SUPPLEMENT silibin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2009-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00915200
The ClinicalTrials.gov registry entry for NCT00915200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which N-acetylcysteine is the first listed.
NCT00915200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00915200 about?
NCT00915200 is a clinical study titled "N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy". The study is designed to test if the combination of two potent antioxidant nutritional supplements, N-acetylcysteine and the milk thistle extract silibin, is capable of correcting the shedding of urine protein, the oxidative stress, and the inflammation in patients with type 2 diabetes mellitus and ...
What is the current status of trial NCT00915200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2009-10. Estimated completion is 2016-04.
What interventions are being tested in trial NCT00915200?
The interventions under investigation include: N-acetylcysteine (DIETARY_SUPPLEMENT), silibin (DIETARY_SUPPLEMENT), high-dose silibin (DIETARY_SUPPLEMENT), N-acetylcysteine placebo (DIETARY_SUPPLEMENT), silibin placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00915200?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.